{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:08:32Z","timestamp":1789589312921,"version":"build-2803163510"},"reference-count":22,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Early termination of clinical trials delays scientific progress and wastes resources, yet factors associated with trial completion in genitourinary (GU) oncology remain incompletely characterized. We investigated trial-level factors associated with premature discontinuation of phase II-III GU oncology clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>We analyzed US phase II-III interventional GU oncology trials registered on ClinicalTrials.gov that were completed or terminated between January 1, 2005, and January 1, 2025. Prespecified operational and trial-level characteristics at initiation included disease site, phase, randomization, masking, sponsor type, number of sites, multinational status, data monitoring committee (DMC) presence, and intervention category. Reasons for early termination were categorized, and associations with premature discontinuation were assessed using multivariable logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 1,597 trials, 445 (27.9%) were terminated early and 1,152 (72.1%) were completed. Poor accrual accounted for 41.8% of terminations, followed by sponsor or business decisions (14.6%) and interim futility or efficacy findings (10.3%). In multivariable analysis, prostate cancer trials were more likely to complete than bladder cancer trials (odds ratio [OR], 1.77, 95% CI, 1.25 to 2.50), as were multinational (OR, 1.96, 95% CI, 1.27 to 3.02) and multisite studies (OR, 1.72, 95% CI, 1.28 to 2.30). Trials enrolling metastatic-only (OR, 0.45, 95% CI, 0.29 to 0.72) or mixed-stage populations (OR, 0.55, 95% CI, 0.36 to 0.86), as well as those with DMC oversight (OR, 0.62, 95% CI, 0.47 to 0.81), were less likely to complete.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>More than one quarter of GU oncology trials terminate prematurely, most often due to accrual failure. Early termination is associated with identifiable disease-specific, structural, and operational trial characteristics. Recognition of these patterns may help inform feasibility assessment, trial planning, and resource allocation, with the goal of reducing preventable trial failure in GU oncology research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-26-00162","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:59:07Z","timestamp":1789588747000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Early Termination of Phase II-III Genitourinary Oncology Trials: A Two-Decade Analysis of Causes and Trial-Level Risk Factors"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4130-8987","authenticated-orcid":true,"given":"Kamil","family":"Malshy","sequence":"first","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4428-9400","authenticated-orcid":true,"given":"Jiacheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Computer Science, Vanderbilt University, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4695-127X","authenticated-orcid":true,"given":"Yusheng","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Environmental Medicine and Public Health Sciences, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Steidle","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2439-7578","authenticated-orcid":true,"given":"Trevor C.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-3823","authenticated-orcid":true,"given":"Denzel","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2243-7402","authenticated-orcid":true,"given":"Suiyue","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Environmental Medicine and Public Health Sciences, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4090-7585","authenticated-orcid":true,"given":"Zijing","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jathin","family":"Bandari","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2021.100843"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1740774514558307"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001432"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.1361"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05818-0"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1633"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127242"},{"key":"e_1_3_8_9_2","unstructured":"CT.GOV: ClinicalTrials.gov glossary terms. https:\/\/clinicaltrials.gov\/study-basics\/glossary"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/UPJ.0000000000000598"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001072"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju229"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5385"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82840-x"},{"key":"e_1_3_8_15_2","volume-title":"Pharmaceutical Industry EMBARKING on a Transformation al era\u2014AI and Medical Big Data\u2014","author":"Kinoshita M","year":"2024","unstructured":"Kinoshita M: Pharmaceutical Industry EMBARKING on a Transformation al era\u2014AI and Medical Big Data\u2014. Tokyo, Japan: Mitsui & Co. Global Strategic Studies Institute; 2024"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00194"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00349"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001191636.31928.db.25"},{"key":"e_1_3_8_19_2","volume-title":"Enhancing Participation in Clinical Trials\u2014Eligibility Criteria, Enrollment Practices, and Trial Designs. Guidance for Industry","author":"Cber FDAC","year":"2025","unstructured":"Cber FDAC: Enhancing Participation in Clinical Trials\u2014Eligibility Criteria, Enrollment Practices, and Trial Designs. Guidance for Industry, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-participation-clinical-trials-eligibility-criteria-enrollment-practices-and-trial-designs"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1300760"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2099-9"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2024.10.034"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102436"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-26-00162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:59:11Z","timestamp":1789588751000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-26-00162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":22,"alternative-id":["10.1200\/OP-26-00162"],"URL":"https:\/\/doi.org\/10.1200\/op-26-00162","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"2026-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-26-00162"}}